GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain
- Conditions
- Pain, Neuropathic
- Interventions
- Drug: SB681323Drug: Placebo
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00390845
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine 134612Biological: Mencevax™ ACWY
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT00390143
- Locations
- 🇩🇰
GSK Investigational Site, Aarhus N, Denmark
A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.
- Conditions
- Osteoporosis
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00388596
- Locations
- 🇺🇸
GSK Investigational Site, Miami, Florida, United States
An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation
- Conditions
- HypercholesterolemiaDyslipidaemiasObesity
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 71
- Registration Number
- NCT00388180
- Locations
- 🇺🇸
GSK Investigational Site, Baton Rouge, Louisiana, United States
Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
- Conditions
- MumpsRubellaMeasles
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00388440
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT00387764
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
- Conditions
- Neoplasms, Breast
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT00388076
- Locations
- 🇺🇸
GSK Investigational Site, Nashville, Tennessee, United States
A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers
- Conditions
- Hyperalgesia
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT00387413
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)
- Conditions
- Neoplasms, Colorectal
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00387387
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, Surrey, United Kingdom
Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00387972
- Locations
- 🇺🇸
GSK Clinical Trials Call Center, Weber City, Virginia, United States